The tools ideate on Boston Scientific’s Farapulse PFA system, which contributed towards a 172% uptick in the company’s Q4 ...

Boston Scientific announced won CE mark for its navigation-enabled Farawave Nav ablation catheter and Faraview software.

Boston Scientific is reaping the rewards from the energised PFA market opportunity in atrial fibrillation treatment.

Farapulse, Boston Scientific’s pulsed field ablation product, fueled year-over-year growth of nearly 171% in the fourth ...

Boston Scientific apparently knows a good bet when it sees one. | That includes treating more than 200,000 patients with the irregular heartbeat known as atrial fibrillation—and the sum more than ...

Argus raised the firm’s price target on Boston Scientific (BSX) to $130 from $105 and keeps a Buy rating on the shares. The firm sees strong ...

Revolutionary new software for the treatment of atrial fibrillation (AFib) has been rolled out for Irish patients in Dublin’s ...

Why it matters: The first year of rolling out Farapulse in the US has been a smashing success, and we think Boston has made the most of its opportunity to upset what had been the long-standing ...

The company’s Electrophysiology (EP) arm continues to gain momentum on the sustained adoption of FARAPULSE PFA. The long-term prospects of the WATCHMAN devices are also encouraging. Meanwhile ...

Boston Scientific Corporation BSX recently presented data supporting the use of the FARAPULSE Pulsed Field Ablation (“PFA”) system and the WATCHMAN Left Atrial Appendage Closure (“LAAC ...

Boston Scientific reported that electrophysiology sales grew 172% in Q4 2024, driven by an uptake of its Farapulse pulsed field ablation (PFA) system. Revealing its Q4 and full-year results ...